EXEL Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: EXEL Shares Outstanding History and EXEL YTD Return |
EXEL Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: EXEL Shares Outstanding History and EXEL YTD Return |
EXEL Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
+16.27% CAGR Mouse over chart for data details
|
EXEL Stock Price Chart |
About Exelixis Inc |
Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. We show 59 historical shares outstanding datapoints in our EXEL shares outstanding history coverage, used to compute EXEL market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing EXEL market cap history over the course of time is important for investors interested in comparing EXEL's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of EXEL versus a peer is one thing; comparing EXEL market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like EXEL can fluctuate over the course of history. With this page we aim to empower investors researching EXEL by allowing them to research the EXEL market cap history. |
EXEL Current Stock Quote |
Free EXEL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Video: The Importance of Market Cap | |
|
EXEL Share Performance |
Market Cap Peers |
Exelixis (EXEL) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
EYE Market Cap History |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.